Howard Federoff and colleagues have identified a ten-metabolite profile in the blood that can determine with 90% certainty whether a cognitively normal elderly person will go on to develop dementia symptoms in the next 2–3 years. The findings could help with patient selection for clinical trials aimed at preventing dementia.